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CASE STUDY
A 52-year-old postmenopausal woman presented with
an abnormal screening mammogram showing a suspi-
cious area in the upper outer quadrant of her left breast.
Core biopsy confirmed an infiltrating ductal carcinoma.
She elected to have a mastectomy, and pathology re-
vealed a 2.6-cm moderately differentiated ductal car-
cinoma with 3 of 16 lymph nodes positive. Hormone
receptors and human epidermal growth factor (HER2)
were negative by immunohistochemistry. Past medi-
cal history and review of systems were unremarkable.
Staging workup was negative, and baseline ejection
fraction was 60% on multiple-gated acquisition scan.
This patient was offered fluorouracil, epirubicin,
and cyclophosphamide followed by docetaxel adjuvant
chemotherapy. She was quite concerned about the po-
tential toxicities of chemotherapy and hoped to con-
tinue to work part-time managing her own business
during treatment.
How can the potential toxicities of this adjuvant
chemotherapy regimen be optimally managed?
DISCUSSION
Many advances have been made in adjuvant therapy
for early-stage breast cancer, contributing to an over-
all decline in mortality. One major advance has been
the addition of taxanes, either concurrently with or
sequentially to anthracycline-based adjuvant chemo-
therapy. The most recent Early Breast Cancer Trialists’
Collaborative Group (2005–2006) overview demon-
strated a 5.1% improvement in overall survival at 10
years for taxane-containing regimens as compared with
anthracycline regimensa.
The PACS 01 trial compared 6 cycles of adjuvant
FEC-100 chemotherapy (5-fluorouracil 500 mg/m2,
epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2)
given intravenously every 3 weeks with 3 cycles of FEC-
100 followed by 3 cycles of docetaxel 100 mg/m2 given
every 3 weeks (FEC-D) in node-positive breast cancer
patients. The sequential taxane containing arm was su-
perior, with an improvement seen in disease-free sur-
vival [hazard ratio (HR): 0.82; 95% confidence interval
(CI): 0.69 to 0.99; p = 0.034] and overall survival (HR:
0.73; 95% CI: 0.56 to 0.94) after 5 years of follow-up1.
In terms of toxicity, more nausea and vomiting,
more grades 3 and 4 neutropenia, and greater use of
granulocyte colony–stimulating factor was seen in the
FEC-100 arm. More febrile neutropenia and stomatitis
were seen in the FEC-D arm. Fewer cardiac events
and acute leukemias occurred in the FEC-D group be-
cause of the lower cumulative anthracycline dose.
The FEC-D regimen was quickly adopted by Cana-
dian medical oncologists. Many were already using
FEC-100 as a standard regimen for node-positive and
high-risk node-negative patients. Single-agent docetaxel
was a standard regimen for metastatic disease, although
dose reductions to 70–80 mg/m2 were commonly used
in that patient group. However, in the adjuvant setting,
docetaxel 100 mg/m2 is used, and many oncologists
reported seeing increased patient toxicity, especially
fatigue, myalgias, and febrile neutropenia.
One of the key factors in toxicity management is
patient education. At the initial oncology consultation,
patients are given a vast amount of information regard-
ing their diagnosis, prognosis, and treatment options.
Verbal and written information on potential side ef-
fects of chemotherapy and their management are pro-
vided by physicians, nurses, and pharmacists. Patients
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often do not absorb all this important information on
first delivery, and they often need it to be repeated.
Before the docetaxel portion of the FEC-D regimen
begins, my institution reviews the toxicities of
docetaxel, highlighting the differences as compared
with FEC-100. The goals of adjuvant treatment are also
reviewed. Patients receiving their chemotherapy in our
regional cancer centres are often seen in our tele-on-
cology clinics.
Fatigue is a common side effect of chemotherapy,
and this fatigue can be both distressing and debilitating.
It is often cumulative, taking longer to improve with
each subsequent chemotherapy cycle. With docetaxel,
onset of fatigue comes earlier—usually 3–5 days post-
drug. Patients have to be cautioned that they will likely
be more fatigued, that the symptoms will start earlier,
and that they may take longer to recover.
Myalgias and arthralgias are a common toxicity of
docetaxel, and these side effects may be severe.
Patients have to be counselled and provided with ap-
propriate analgesia. A longer duration of steroids may
also be helpful.
Febrile neutropenia is common with docetaxel-
containing regimens. Primary prophylaxis is routinely
used in anthracycline–taxane combination regimens
such as TAC (docetaxel, doxorubicin and, cyclophos-
phamide). It may also be considered when using
adjuvant docetaxel 100 mg/m2, especially for patients
at higher risk of neutropenia and its complications.
In striving to better predict who really needs
adjuvant chemotherapy and to develop better predic-
tors of chemotherapy response, attempts must be
made to maximize benefit and minimize toxicity with
available chemotherapy regimens. The FEC-D regi-
men is clearly one that offers benefits in disease-
free and overall survival to patients, and with care,
its additional toxicities can be managed. The best
approach involves a multidisciplinary team effort,
resulting in a well-informed and supported patient.
And in the end, improvement in the patient’s out-
come is worth it.
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